Dr. Richard Finn

Richard Finn, MD

Professor, Department of Medicine, Hematology/Oncology
Physician, Department of Surgery, Dumont-UCLA Liver Cancer Center

Specialty

Hematology, Internal Medicine, Medical Oncology

Languages

English

Education

Fellowship

Hematology/Oncology, UCLA School of Medicine, 2000 - 2003

Internship

Internal Medicine, UCLA School of Medicine, 1997 - 1998

Degree

MD, USC School of Medicine, 1997

Residency

Internal Medicine, UCLA School of Medicine, 1998 - 2000

Board Certifications

Hematology, American Board of Internal Medicine, 2003
Medical Oncology, American Board of Internal Medicine, 2003
Internal Medicine, American Board of Internal Medicine, 2000

Contact Information

Phone

(310) 206-3180 - Office
(310) 829-5471 - Santa Monica office
(310) 206-1446 - Gastrointestinal Oncology information and referral
(310) 825-1412 - Dumont-UCLA Liver Cancer Center information and referral
(310) 206-3748 - Dumont-UCLA Liver Cancer Center referring physician
(310) 206-6931 - UCLA Oncology Center information and patient appointments
(310) 206-6909 - UCLA Oncology Center information and patient appointments

Clinical Interests

Biliary, Breast, Cancers of the Digestive Tract, Gastrointestinal, General Hematology, General Oncology, Hepatobiliary, Liver

Scientific Interests

Dr. Richard Finn's research and clinical interests are in treating liver and breast cancer.

Highlighted Publications

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006; 12(9): 2817-25.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3): 1630-9.

Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004; 3(12): 1243-9.

Finn RS, Slamon DJ. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 2003; 21: 223-33.

In the News

View more articles